Shenzhen Jingdan Biopharmaceutical Technology

CrystalO Biopharma, established in August 2019, focuses on the research and development of innovative ion channel drugs targeting major diseases such as depression, pain, and chronic kidney disease. The company operates in the biopharmaceutical sector, leveraging advanced technologies and expertise in molecular cloning, protein expression, and purification systems. CrystalO's core team comprises distinguished scientists from top institutions like Harvard University and the Chinese Academy of Sciences. The company utilizes cutting-edge techniques, including lipid cubic phase method and cryo-electron microscopy (cryo-EM), to develop its products. CrystalO's business model revolves around the discovery and development of novel therapeutics, which are then licensed to pharmaceutical companies or brought to market through strategic partnerships. Revenue is generated through licensing fees, milestone payments, and royalties from commercialized products. The company serves a global market, addressing unmet medical needs with a focus on ion channel drug targets, which are crucial for treating a wide range of diseases.

Keywords: ion channel drugs, depression, pain, chronic kidney disease, molecular cloning, protein expression, cryo-EM, biopharmaceutical, innovative therapeutics, strategic partnerships.